Canada markets closed
  • S&P/TSX

    20,206.41
    +106.60 (+0.53%)
     
  • S&P 500

    4,008.01
    -15.88 (-0.39%)
     
  • DOW

    32,223.42
    +26.76 (+0.08%)
     
  • CAD/USD

    0.7781
    +0.0034 (+0.43%)
     
  • CRUDE OIL

    114.00
    -0.20 (-0.18%)
     
  • BTC-CAD

    38,679.43
    -1,601.64 (-3.98%)
     
  • CMC Crypto 200

    667.04
    +424.36 (+174.87%)
     
  • GOLD FUTURES

    1,822.90
    +8.90 (+0.49%)
     
  • RUSSELL 2000

    1,783.43
    -9.24 (-0.52%)
     
  • 10-Yr Bond

    2.8770
    -0.0580 (-1.98%)
     
  • NASDAQ futures

    12,262.25
    +17.50 (+0.14%)
     
  • VOLATILITY

    27.47
    -1.40 (-4.85%)
     
  • FTSE

    7,464.80
    +46.65 (+0.63%)
     
  • NIKKEI 225

    26,547.05
    +119.40 (+0.45%)
     
  • CAD/EUR

    0.7457
    +0.0021 (+0.28%)
     

MedX Health Corp. Launches DermSecure Screening Services with Medicure Clinic

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

MedX Health, in partnership with Medicure Clinic, launches DermSecure® Screening Platform Services in Mississauga, Ontario

MISSISSAUGA, Ontario, January 20, 2022--(BUSINESS WIRE)--MedX Health Corp. ("MedX" or the "Company") (TSXV: MDX), a global leader in teledermatology, and the Medicure Clinic ("Medicure" or the "Clinic") are pleased to announce the launch of MedX Screening Services at Medicure, a physician-owned clinic that also houses a pharmacy. MedX’s scanning services are now available to the Clinic’s roster of 5,000 existing family physician patients as well as walk-in patients through the on-site pharmacy.

"We are delighted to work with the Medicure Clinic and help them make our technology accessible to their patients as well as walk-in customers via their on-site pharmacy," stated MedX VP of North American Sales, Paul Ziemer. "Medicure, located in the heart of Mississauga, serves many new Canadian families and MedX’s DermSecure platform will help improve access to dermatological services for this underserved community. Medicure is a physician-owned clinical practice; this again illustrates the value that MedX and the DermSecure platform bring to the service that our dedicated healthcare partners provide to their communities every day."

Medicure Clinic now offering MedX Health DermSecure® Screening Services:

Mississauga, Ontario

  • 70 Queen Street South, Mississauga

    • 2 Family Physicians on staff

    • In-house pharmacy for walk-in patients

    • 2 Pharmacists on staff

To date, the MedX business model has been focused on multiple market verticals, such as Medical Clinic and Building Hubs, Pharmacies, Medical Scanning Clinics, Mobile and Remote Medical Practices, Esthetics and Skin Care Clinics. The partnership with Medicure Clinic is the first launch of the MedX DermSecure® Screening Platform within a blended physician and pharmacy clinic setting in Canada.

Implementing MedX's physician- and pharmacy-based model with Medicure serves to relieve the pressure facing their family physicians, allowing them to alleviate the stress of melanoma screening for their roster of patients in their practice quickly and efficiently. It also addresses patient concerns over the current long wait times to consult with a dermatologist for mole screenings and inflammatory conditions such as acne, psoriasis and eczema.

Additionally, the blended model allows walk-in patients of a pharmacy to get service for their dermatology concerns if they do not have a family doctor or do not have time to get a direct referral. This blended model is also very efficient in medical buildings, where the physicians can send their patients (both walk-in and existing roster) to the pharmacy to have their screenings done. This allows for prescriptions and product recommendations from the dermatologist to be fulfilled at the pharmacy.

Naman Demaghlatrous, MedX Managing Director, said, "Our partnership with the Medicure Clinic provides early and rapid detection of melanoma and improves patient outcomes in a burdened healthcare climate. People's ever-increasing awareness and motivation to focus on their health and wellness are shifting to a more patient-centric behaviour and is perfectly suited to MedX's technology platform. We foresee adding many more agreements like this to ensure we can maximize our growth potential and realize our purpose of saving lives."

Teledermatology is a subspecialty of dermatology that offers safe and effective virtual care – patient screening and assessment – eliminating the need for in-person appointments with a dermatologist. MedX is a global leader in teledermatology through its high-definition image capture technology, SIAscopy®, and its secure, cloud-based patient management system, DermSecure®, which securely transmits and stores patient data throughout the assessment process. MedX's SIAscopy® is the only technology globally that captures five high-resolution images of suspicious moles, lesions and skin conditions, including four spectrophotometric images 2mm below the skin's surface. This technology provides detailed patient scans for virtual dermatological assessment by a certified dermatologist within 72 hours.

About MedX Health Corp.:

MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. Visit https://medxhealth.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220120005427/en/

Contacts

Bill Mitoulas, Investor Relations
MedX Health Corp.
bill@medxhealth.com
+1-416-479-9547

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting